| Abnormal involuntary movements scale | AIMS |
| Alzheimer’s disease | AD |
| Antisense Oligonucleotide | ASO |
| Blood-brain barrier | BBB |
| Brain-derived neurotrophic factor | BDNF |
| Clustered regularly interspaced short palindromic repeats-CRISPR-associated system | CRISPR-Cas9 |
| Cerebrospinal fluid | CSF |
| Cytosine-adenine-guanine | CAG |
| Eicosapentaenoic acid | EPA |
| Electron transport chain | ETC |
| Food and Drug Administration | FDA |
| Huntington disease | HD |
| Huntingtin gene | HTT |
| micro RNA | miRNA |
| Mini-mental state examination | MMSE |
| Mutant huntingtin protein | mHTT |
| Mammalian target of rapamycin | mTOR |
| 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine | MPTP |
| N-methyl-D-aspartate | NMDA |
| Parkinson’s disease | PD |
| RNA Interference | RNAi |
| small interfering RNA | siRNA |
| Spinal muscular atrophy | SMA |
| Suberoylanilide hydroxamic acid | SAHA |
| Tauroursodeoxycholic acid | TUDCA |
| Tetrabenazine | TBZ |
| Total functional capacity | TFC |
| Total motor score | TMS |
| Unified HD rating scale | UHDRS |
| Vesicular monoamine transporter 2 | VMAT2 |
| Zinc finger proteins | ZFPs |